Early versus delayed invasive strategy for intermediate‐ and high‐risk acute coronary syndromes managed without P2Y₁₂ receptor inhibitor pretreatment: Design and rationale of the EARLY randomized trial

By  

Clinical Cardiology, Vol. 41, Iss. 1, 2018-01 ,pp. : 5-12

John Wiley & Sons Inc

Access to resources Recommend Favorite

N-terminal pro-brain natriuretic peptide in relation to inflammation, myocardial necrosis, and the effect of an invasive strategy in unstable coronary artery disease

By Jernberg T.   Lindahl B.   Siegbahn A.   Andren B.   Frostfeldt G.   Lagerqvist B.   Stridsberg M.   Venge P.   Wallentin L.  

Journal of the American College of Cardiology, Vol. 42, Iss. 11, 2003-12 ,pp. : 1909-1916

Elsevier

Access to resources Recommend Favorite

Drug-induced thrombocytopenia and thrombosis: Evidence from patients receiving an oral glycoprotein IIb/IIIa inhibitor in the Orbofiban in Patients with Unstable coronary Syndromes- (OPUS-TIMI 16) trial

By Scirica Benjamin   Cannon Christopher   Cooper Richard   Aster Richard   Brassard Jacqueline   McCabe Carolyn   Charlesworth Andrew   Skene Allan   Braunwald Eugene  

Journal of Thrombosis and Thrombolysis, Vol. 22, Iss. 2, 2006-10 ,pp. : 95-102

Springer Publishing Company

Access to resources Recommend Favorite

Impact of diabetes mellitus on long-term outcome after unstable angina and non-ST-segment elevation myocardial infarction treated with a very early invasive strategy

By Müller C.   Neumann F.   Ferenc M.   Perruchoud A.   Büttner H.  

Diabetologia, Vol. 47, Iss. 7, 2004-07 ,pp. : 1188-1195

Springer Publishing Company

Access to resources Recommend Favorite

Immune-Inflammatory Activation in Acute Coronary Syndromes: A Look into the Heart of Unstable Coronary Plaque

By  

Current Cardiology Reviews, Vol. 13, Iss. 2, 2017-03 ,pp. : 110-117

Bentham Science Publishers

Access to resources Recommend Favorite